Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04977375 · ClinicalTrials.gov registry record · Phase 1
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
A Phase 1 study of Glioblastoma Multiforme, sponsored by Chirag G. Patil.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04977375 is a Phase 1 study of Glioblastoma Multiforme that is actively recruiting participants, run by Chirag G. Patil. The registered enrollment target is 10 participants, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04977375, a Phase 1 study of Glioblastoma Multiforme, is actively recruiting participants, sponsored by Chirag G. Patil.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety/tolerability/feasibility of pembrolizumab and radiation therapy before surgical resection in patients with recurrent glioblastoma as defined by treatment-related AEs and the number of patients who do not necessitate a delay in surgical resection, and to assess overall survival. The secondary objectives are to assess progression free survival, and to assess the T cell clonality, CD8 T cell activation and Tumor Infiltrating Lymphocyte (TIL) score after treatment
Conditions Studied
Interventions
- DRUG Pembrolizumab
- RADIATION Stereotactic Radiation Therapy
- PROCEDURE Surgical Resection
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-12-09 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04977375
The ClinicalTrials.gov registry entry for NCT04977375 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (90% lower). The listed sponsor is Chirag G. Patil, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04977375 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04977375 about?
NCT04977375 is a clinical study titled "Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma". The purpose of this study is to assess the safety/tolerability/feasibility of pembrolizumab and radiation therapy before surgical resection in patients with recurrent glioblastoma as defined by treatment-related AEs and the number of patients who do not necessitate a delay in surgical resection, and...
What is the current status of trial NCT04977375?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2021-12-09. Estimated completion is 2026-12.
What conditions does trial NCT04977375 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT04977375?
The interventions under investigation include: Pembrolizumab (DRUG), Stereotactic Radiation Therapy (RADIATION), Surgical Resection (PROCEDURE).
Who is sponsoring clinical trial NCT04977375?
This trial is sponsored by Chirag G. Patil, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04977375 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
-
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.